Over the past 2 decades, there have been significant innovations in the management of type 1 diabetes (T1D). Automation in closed-loop systems offers the potential to reduce diabetes burden and improve glucose profile.
1 There are several automated insulin delivery platforms using various combinations of insulin pumps, continuous glucose monitor (CGM) systems, and algorithms. The MiniMed 670G (Medtronic) insulin pump was the first commercial system to be available after regulatory approval, based on findings from a 3-month single-arm observational study.
2 The study also reported improved glycemic control, with increased time in range (TIR) and reductions in hemoglobin A
1c (HbA
1c), compared with baseline.
3 The hybrid closed-loop (HCL) system uses a control algorithm that delivers insulin based on CGM glucose measures. However, meals must still be announced and an insulin bolus delivered according to meal carbohydrate content.